ID   MCF-7/TMX2
AC   CVCL_4Y63
SY   TMX2
DR   cancercelllines; CVCL_4Y63
DR   Wikidata; Q54904388
RX   PubMed=12943988;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4Y65 ! MCF-7 clone 33
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=12943988; DOI=10.1016/S0303-7207(03)00256-9;
RA   Fasco M.J., Amin A., Pentecost B.T., Yang Y., Gierthy J.F.;
RT   "Phenotypic changes in MCF-7 cells during prolonged exposure to
RT   tamoxifen.";
RL   Mol. Cell. Endocrinol. 206:33-47(2003).
//